Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Vaddepally, R.K.; Kharel, P.; Pandey, R.; Garje, R.; Chandra, A.B. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers 2020, 12, 738. https://doi.org/10.3390/cancers12030738
Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers. 2020; 12(3):738. https://doi.org/10.3390/cancers12030738
Chicago/Turabian StyleVaddepally, Raju K., Prakash Kharel, Ramesh Pandey, Rohan Garje, and Abhinav B. Chandra. 2020. "Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence" Cancers 12, no. 3: 738. https://doi.org/10.3390/cancers12030738